A narrative review on vaccination rate and factors associated with the willingness to receive pneumococcal vaccine in Chinese adult population

Hum Vaccin Immunother. 2022 Nov 30;18(6):2139123. doi: 10.1080/21645515.2022.2139123. Epub 2022 Nov 15.

Abstract

The 23-valent pneumococcal polysaccharide vaccine (PPSV-23) is the only approved vaccine for pneumococcal diseases in elderly Chinese population. Though regional studies explored the PPSV-23 vaccination coverage rates and influencing factors in China, a large-scale, nation-wide epidemiological surveillance studies to understand the different factors impeding pneumococcal vaccination rate are required. Hence, this review summarized PPSV-23 coverage rate, analyzed and identified vaccination influencing factors among elderly population across China by exploring articles published in CNKI, Wanfang and PubMed databases. Pneumococcal vaccination coverage rate was found to be low at around 1.23%~42.10% in China. Co-morbidities, knowledge, attitude, perception toward pneumonia and PPSV-23, education level, socio-economic disparities, health education and local policies were some of the factors associated with vaccination willingness among elderly Chinese population. Interventions or policies like government funding, subsidies, inclusion of PPSV-23 in medical insurance, or systematic encouragement from HCPs as key strategies should be implemented to encourage vaccination.

Keywords: 23-valent pneumococcal polysaccharide vaccine; China; PPSV-23; elderly population; pneumococcal vaccine; pneumonia; willingness.

Publication types

  • Review

MeSH terms

  • Adult
  • Aged
  • East Asian People*
  • Humans
  • Pneumococcal Infections* / epidemiology
  • Pneumococcal Infections* / prevention & control
  • Pneumococcal Vaccines
  • Streptococcus pneumoniae
  • Vaccination

Substances

  • Pneumococcal Vaccines

Grants and funding

This work was supported by the MSD China, Shanghai, China and by 2021 Beijing Key Specialty Program for Major Epidemic Prevention and Control.